Grabar Law Office Investigates Claims on Behalf of Shareholders of CareDx, Inc. (CDNA)

Philadelphia, Pennsylvania--(Newsfile Corp. - November 30, 2022) - It is alleged that certain officers of CareDx caused the Company to issue materially false and misleading statements regarding its testing services. Specifically, the Company failed to disclose that certain CareDx officers had engaged in a number of improper and illegal schemes to inflate testing services revenue, including: (i) encouraging protocols for surveillance of organ rejection through inaccurate marketing materials and in violation of Medicare standards; (ii) offering inducements or kickbacks to physicians and other providers; and (iii) improperly bundling expensive testing services with other blood tests as part its RemoTraC service. As a result of these business practices, CareDx has been the subject of at least three government investigations including one by the U.S. Department of Justice ("DOJ") relating to a False Claims Act investigation, one by the SEC, and one by an unnamed state regulatory agency.

If you are a current CareDx shareholder who has held shares since on or before February 24, 2021, you may be able seek corporate reforms, the return of funds expended defending litigation back to company coffers, and a court approved incentive award if appropriate.

If you would like to learn more about this matter at no cost to you, visit https://grabarlaw.com/the-latest/caredx-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085.

Attorney Advertising Disclaimer

These materials have been prepared by the Grabar Law Office for informational purposes only and does not constitute legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Prior results referred to in these materials do not guarantee or suggest a similar result in other matters.

Contact:

Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/146322